我們已在上線! 進一步了解
LJPC

La Jolla Pharmaceutical Company

已下市

LJPC已於2022年8月19日下市。

 

關於: La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.

員工: 66

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於LJPC的最新新聞文章。

價格圖表採用Lightweight Charts™實作